US-based Inceptor Bio has entered into a partnership with Chinese firm GRIT Biotechnology to advance the potential best-in-class chimeric antigen receptor (CAR)-T therapy, IB-T101, for the treatment of solid tumors. This collaboration combines the expertise of two cell therapy specialists to enhance the development and commercialization of innovative cancer treatments.
Program Details and Technology
IB-T101 is Inceptor Bio’s autologous CD70 CAR-T program, which utilizes the proprietary OUTLAST platform to reprogram T cells for superior stemness, durability, and effector function in the hostile tumor microenvironment. The program specifically targets clear cell Renal Cell Carcinoma (ccRCC), a cancer with significant unmet medical need and over 300,000 new cases annually worldwide.
Agreement Terms
Under the terms of the agreement, GRIT Biotechnology will be responsible for the development, manufacturing, and commercialization of IB-T101 in China. Inceptor Bio is eligible to receive an undisclosed amount of milestone payments and royalties. Clinical data from the collaboration is expected to support regulatory filing and development in other territories.
Significance of the Partnership
This strategic collaboration underscores the commitment of both Inceptor Bio and GRIT Biotechnology to advancing cutting-edge CAR-T therapies. By leveraging their combined expertise, the companies aim to accelerate the development of IB-T101 and bring innovative treatment options to patients with solid tumors, particularly those suffering from ccRCC.-Fineline Info & Tech
Leave a Reply